1448 Results
Sort By:
Published on October 5, 2022
A team of researchers at the University of Texas MD Anderson Cancer Center say they have developed a novel approach to the engineering of natural killer (NK) cells that improves tumor specificity and anti-tumor activity. The newly developed cells overcome NK cell dysfunction and tumor relapse via the addition of…
Published on September 21, 2022
Researchers at Friedrich-Alexander-University Erlangen-Nürnberg (FAU), in Germany have successfully cured several patients suffering from severe systemic lupus erythematosus (SLE) using genetically modified immune cells known as CAR-T cells. CAR T cells are immune cells taken from an individual patient and genetically engineered to express proteins known as CAR—chimeric antigen receptors—on…
Published on September 21, 2022
Calibr, the drug discovery and development division of Scripps Research, reports positive Phase I results for its next generation switchable CAR-T cell therapy platform in patients with B cell cancers. In a presentation today at the CAR-TCR Summit in Boston, the researchers announced that six of nine patients treated with…
Published on September 7, 2022
Researchers at UT Southwestern Simmons Cancer Center report that lactate, a metabolic byproduct produced by cells during strenuous exercise, may rejuvenate immune cells that fight cancer. Their findings, published in Nature Communications, could eventually be used to develop new strategies to augment the anti-tumor effect of cancer immunotherapies. “The lactate that…
Published on August 31, 2022
Scientists Cedars-Sinai Medical Center have discovered that some types of highly aggressive soft-tissue sarcoma tumors create high levels of the protein macrophage migration inhibitory factor (MIF), a protein that normally blocks tumor growth. But instead of blocking cancer, MIF does the opposite in these sarcomas, ultimately leading to tumor growth.…
Published on August 17, 2022
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. According to the American Cancer Society, the five-year survival rate for patients with localized liver cancer is…
Published on July 29, 2022
Biosimulation company Certara announced on Thursday that is has entered a two-year collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to develop new biosimulation software aimed at improved CAR T-cell therapy dosing for multiple myeloma patients. “We are very pleased to work with MSK, a leading cancer hospital and research…
Published on June 22, 2022
Scientists from Cedars-Sinai Medical Center report they used single-cell RNA-sequencing to characterize the immune composition of an undifferentiated pleiomorphic sarcoma mouse model. The scientists observed that soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. Findings could lead to improved treatments for soft-tissue sarcomas. This work…
Published on June 15, 2022
There has been a growing body of work investigating the role of innate lymphoid cells (ILCs) in immunity and host defense. The more we learn about them, the more we recognize that innate lymphoid cells comprise a crucial part of the innate immune response. This includes our ability to contain…
Published on June 13, 2022
A new lab study shows additional treatment with interleukin 7 (IL-7) after CAR-T cell infusion makes the therapeutic cells grow in number and become more effective at tumor killing. The Washington University School of Medicine in St. Louis team’s report was published today in Nature Communications. “Many researchers are trying different…
Published on June 8, 2022
Libraries of immune cells displaying diverse repertoires of chimeric antigen receptors (CARs) have been developed that can recognize non-self antigens and display antigen-dependent clonal expansion, with the expanded population of tumor-specific effector cells leading to long-lasting antitumor responses in mouse models of epithelial tumors. Over the past decade, substantial progress…
Published on June 8, 2022
Researchers at Imagine Pharma, a regenerative medicine company based in Pittsburgh, Philadelphia, have engineered pancreatic cells from someone with long term type 1 diabetes and enabled them to produce insulin. While the work is still in its early stages, if validated it could allow a patient’s own cells to be…
Published on June 1, 2022
Targeted radiation with stereotactic radiosurgery (SRS) may be as good as whole brain radiotherapy (WBRT) for the treatment of brain metastases in people with small-cell lung cancer (SCLC), suggest results of a meta-analysis carried out by researchers from the University of Toronto in Ontario, Canada. The findings challenge previous concerns…
Published on May 11, 2022
A droplet-based microfluidic technology produces micro-organospheres (MOSs) from cancer patient biopsies within an hour, according to a new report led by researchers at the Terasaki Institute for Biomedical Innovation (TIBI). They detail how patient tumor, immune, and connective tissue cells quickly form miniature tumors that retain the original microenvironment within…
Published on April 28, 2022
Genes not previously associated with congenital heart disease have been linked to such conditions, according to new findings from a multi-center study. The researchers also shed new light on the role of CHD4 in inborn heart disease. This work was led by Frank Conlon, PhD, professor of biology and genetics…